- Home
- XFOR vs SLGL Comparison
XFOR vs SLGL Comparison
Compare XFOR & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- SLGL
- Stock Information
- Founded
- XFOR 2014
- SLGL 1997
- Country
- XFOR United States
- SLGL Israel
- Employees
- XFOR N/A
- SLGL N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- SLGL Health Care
- Exchange
- XFOR Nasdaq
- SLGL Nasdaq
- Market Cap
- XFOR 84.3M
- SLGL 69.1M
- IPO Year
- XFOR N/A
- SLGL 2018
- Fundamental
- Price
- XFOR $3.42
- SLGL $40.01
- Analyst Decision
- XFOR Strong Buy
- SLGL
- Analyst Count
- XFOR 3
- SLGL 0
- Target Price
- XFOR $34.17
- SLGL N/A
- AVG Volume (30 Days)
- XFOR 412.4K
- SLGL 21.2K
- Earning Date
- XFOR 11-12-2025
- SLGL 11-14-2025
- Dividend Yield
- XFOR N/A
- SLGL N/A
- EPS Growth
- XFOR N/A
- SLGL N/A
- EPS
- XFOR N/A
- SLGL N/A
- Revenue
- XFOR $32,774,000.00
- SLGL $23,931,000.00
- Revenue This Year
- XFOR $1,307.51
- SLGL N/A
- Revenue Next Year
- XFOR N/A
- SLGL $31.17
- P/E Ratio
- XFOR N/A
- SLGL N/A
- Revenue Growth
- XFOR 5721.31
- SLGL 264.86
- 52 Week Low
- XFOR $1.35
- SLGL $4.01
- 52 Week High
- XFOR $26.83
- SLGL $52.26
- Technical
- Relative Strength Index (RSI)
- XFOR 52.78
- SLGL 74.00
- Support Level
- XFOR $3.35
- SLGL $27.00
- Resistance Level
- XFOR $3.63
- SLGL $52.26
- Average True Range (ATR)
- XFOR 0.31
- SLGL 4.40
- MACD
- XFOR -0.03
- SLGL 0.95
- Stochastic Oscillator
- XFOR 61.97
- SLGL 57.87
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.